Aardvark Therapeutics IPO
NASDAQ: AARD
Aardvark Therapeutics completed their IPO on February 12, 2025. Now that Aardvark Therapeutics is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies to modulate the gut-brain axis for treating metabolic diseases and hunger-related disorders. Its lead compound, ARD-101, is an oral TAS2R (bitter taste receptor) pan-agonist that stimulates the release of satiety hormones like GLP-1 and cholecystokinin (CCK) from enteroendocrine cells in the digestive tract.
Sign up for SecondMarket® to invest in or sell private companies like Aardvark Therapeutics before their IPO.
Buy + SellSee Aardvark Therapeutics Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Aardvark Therapeutics Stock Valuation + Share Prices
View real-time Tape D® data on Aardvark Therapeutics stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket trading platform.
Get Started
Aardvark Therapeutics Management Team - Prior to IPO
-
Board Member
Victor Tong
-
Board Member
Jeffrey Chi
-
CEO, Board Member
Tien-Li Lee
-
CFO
Nelson Sun
-
Chief Commercial Officer
Danny Villeneuve
-
Chief Medical Officer
Manasi Jaiman
-
Chief Research Officer
Zhenhuan Zheng
-
Chief Scientific Officer
Tim Kieffer
-
COO
Bryan Jones
Learn More About Aardvark Therapeutics Stock
Buy Aardvark Therapeutics Stock
01Aardvark Therapeutics became publicly traded following its IPO on February 12, 2025, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: AARD. Before the IPO, Aardvark Therapeutics stock was privately held and available only through private market transactions.
If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.
Sell Aardvark Therapeutics Stock
02Following its IPO on February 12, 2025, Aardvark Therapeutics shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.
If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.
Aardvark Therapeutics Stock Price
03Following the IPO, Aardvark Therapeutics stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Aardvark Therapeutics’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.
Aardvark Therapeutics Stock Ticker Symbol
04Following its IPO on February 12, 2025, Aardvark Therapeutics stock now trades on public markets under the ticker symbol NASDAQ: AARD. You can view real-time stock information through widely used financial data platforms.
Criteria to Sell Aardvark Therapeutics Stock
05Following the Aardvark Therapeutics IPO, public shares can be sold through any brokerage.
Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Criteria to Buy or Invest in Aardvark Therapeutics Stock
06Following Aardvark Therapeutics’s initial public offering on February 12, 2025, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Aardvark Therapeutics stock can do so through their preferred broker, just as they would with any other publicly traded security.
Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Aardvark Therapeutics Stock Settlement
07Since Aardvark Therapeutics is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.
Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Aardvark Therapeutics IPO
08Aardvark Therapeutics completed its IPO on February 12, 2025, and is now publicly available through major financial sources.
Sign up for SecondMarket® to invest in or sell private companies like Aardvark Therapeutics before their IPO.
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.